Aerie Pharmaceuticals — Investor Presentation (August 2019)
21 slides from Aerie Pharmaceuticals's investor presentation, Aug 13, 2019
Slide 1: Company Overview Investor Presentation
Exhibit 99.1 Company Overview Investor Presentation August 2019
Slide 2: Important Information
Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) in this presentation are qualified in their entirety
Slide 3: Aerie Overview
Aerie Overview Aerie IOP–Reducing Products (IP 2030+) • Rhopressa® (netarsudil ophthalmic solution) 0.02% • Successful U.S. Launch in 2018 • Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% • Launched May 1, 2019 • Second drug product contract manufacturer approved for Rhopre
Slide 4: Glaucoma Market Perspective
Glaucoma Market Perspective CAI Lumigan 6% 7% Travatan 5% 2018 U.S. Glaucoma Market AA 10% - ~$3B Market, 35M TRx, 52M bottles Fixed - Half of volume first-line (PGAs) Combo Latanoprost - Half of volume 2-3X/Day Adjuncts 13% 41% BB 14% Other Graph Source: IQVIA 2018 CAI: Carbonic Anhydrase Inhibitor
Slide 5: Rhopressa and Rocklatan Positioning
Rhopressa ® and Rocklatan ® Positioning Rhopressa® Positioning Rocklatan® Positioning HCP’s positioning as HCP’s positioning as therapy concomitant therapy for patients requiring maximal IOP lowering with one drop per day • Efficacy vs. other adjunctive therapies • Efficacy vs. all other glaucoma th
Slide 6: Rocklatan Phase 3 Month 12 Responder Analysis: Goal is to Achieve Lowest IOP Possible
Rocklatan® Phase 3 Month 12 Responder Analysis: Goal is to Achieve Lowest IOP Possible At Month 12: % of Patientswith IOP Reduced to 18 mmHg or Lower 100% ** 82% 80% *** 72% *** 66% 60% 60% 57% ** 49%49% 43% 40% * 37%35% 27% 26% 22% 20% 16% 12% 0% 14 mmHg 15 mmHg 16 mmHg 17 mmHg 18 mmHg IOP on Treat
Slide 7: U.S. Glaucoma Franchise Launch Update
U.S. Glaucoma Franchise Launch Update Actual Sales-Out to Pharmacies data and IQVIA data as of 8/2/19 15,000 Franchise Actual Sales-Out to Pharmacies Rhopressa® Actual Sales-Out to Pharmacies 14,199 Franchise IQVIA Bottles 11,858 12,000 Rhopressa® IQVIA Bottles 11,294 Franchise IQVIA Rx 9,598 9,000
Slide 8: Gaining Market Access
Gaining Market Access • Rhopressa® Access as of August 2019: – Commercial ~ 90% – Medicare Part D ~ 75% • Rocklatan® Expected Access by end of September 2019: – Medicare Part D ~ 30% (Rhopressa® ~10% in September 2018) Access percentages reflect signed contracts, not necessarily implemented underlyi
Slide 9: 2019 Financial Guidance
2019 Financial Guidance • Net revenue guidance: $70 to $80 million • Net cash burn guidance: $160 to $170 million For Investor Use 9
Slide 10: Launch Considerations
Launch Considerations • Aerie is in the unique position of gaining coverage for Rocklatan® while continuing to grow Rhopressa® – Underlying formulary coverage is sometimes delayed • Physicians are navigating through the treatment paradigm to optimize patient care while considering patient costs • Ro
Slide 11: Active Engagement at Key Conferences
Active Engagement at Key Conferences • March 2019: American Glaucoma Society (AGS) • April/May 2019: Association of Research in Vision and Ophthalmology (ARVO) • May 2019: American Society of Cataract and Refractive Surgeons (ASCRS) • July 2019: American Society for Retina Specialists (ASRS) • Septe
Slide 12: Expanding Aerie Franchise: Europe
Expanding Aerie Franchise: Europe • MAA accepted for Rhokiinsa® (Rhopressa ®) in October 2018, regulatory decision expected by end of 2019 • Mercury 3: 6-month safety and 90-day efficacy registration trial comparing Rocklatan® (known as Roclanda ® in Europe) for non-inferiorityto a fixed-dose combo
Slide 13: Expanding Aerie Franchise: Japan
Expanding Aerie Franchise: Japan • Advancing clinical development on our own, established branch office in Tokyo • Phase 1 completed; successful Pilot Phase 2 completed in the U.S. on Japanese and Japanese-Americans; Phase 2 commenced in Japan, enrollment completed July 2019 • Phase 2 Study top-line
Slide 14: Advancing the Pipeline
Advancing the Pipeline Development Stage Drug/Target Indication Discovery Preclinical Phase 1/2a AR-1105 Implant RVO (Dexamethasone) wAMD IND AR-13503 Implant DME/DR IND (ROCK, PKC) Glaucoma Neuro- enhancement AR-xxxxx Implant Dry AMD/GA (ROCK/JAK/IKK) AR-xxxxx Dry Eye/MGD (JAK, IKKb) AR-xxxxx Psori
Slide 15: Retinal Eye Diseases – Aerie's Next Chapter
Retinal Eye Diseases – Aerie’s Next Chapter Bringing Small Molecule Therapy to Back of the Eye • Most retinal drugs in use and in pipeline are protein therapeutics • Longer half-life allows monthly to bimonthly IVT injections • Protein therapeutics address limited number of extracellular targets • S
Slide 16: 2018 U.S. Retinal Disease Market
2018 U.S. Retinal Disease Market 2018 Sales: $6.0B 2018 Unit Sales: 7.3MM steroids, others, steroids, others, $0.2 $0.02 0.2 0.1 Lucentis, 1.0 Eylea, 2.1 Lucentis, $1.7 Eylea, $4.1 Avastin, $0.04 Avastin, 3.9 Sources: Mixture of public information, IQVIA, Market-Scope and estimates – March 2019 For
Slide 17: Aerie's Innovation in Retinal Disease
Aerie’s Innovation in Retinal Disease Small Molecule Drug Proprietary Drug Delivery Candidates Technology • DSM PEA Polymer • PLGA • Aerie Kinase Library • PRINT® Mfg • Non-Aerie drug candidates • Bio-erodible, sustained-release implant for intravitreal injection AMD DME RVO Dry AMD/GA Glaucoma Othe
Slide 18: Retinal Eye Disease: Unmet Needs in AMD and DME
Retinal Eye Disease: Unmet Needs in AMD and DME • Need new treatments to address disease mechanisms beyond VEGF • Complex pathology cannot be addressed by a single drug class • Anti-VEGFs are used to treat the eye with wet AMD, while the second eye typically has dry AMD and a high risk of converting
Slide 19: Aerie's Lead Retina Product Candidates
Aerie’s Lead Retina Product Candidates AR-1105 (Dexamethasone) Implant • Indications: retinal vein occlusion (RVO) and DME • Target product profile vs. Ozurdex® • Longer duration of efficacy (6 mo vs 3 mo) • Improved administration due to smaller needle • Potential for fewer adverse effects due to l
Slide 20: AR-13503 Synergistic to Eylea in Mouse Model of Proliferative Diabetic Retinopathy
AR-13503 Synergistic to Eylea® in Mouse Model of Proliferative Diabetic Retinopathy Oxygen-induced retinopathy (OIR) mouse model - PDR Neovascular Area (+SEM) *** 35% 30% * * : p<0.01 *** : p<0.0001 25% -40% 20% -60% 15% 10% 5% 0% Vehicle Eylea (sub- AR-13503 (sub- Combination n=12 optimal dose) opt
Slide 21: Summary
Summary • Key Priorities • Rhopressa®: Continued successful launch execution • Rocklatan®: Successful launch execution • Globalization Strategy • Europe/Japan clinical path and commercialization strategy • Ireland Manufacturing Facility • Research Initiatives • Rhopressa® normal tension glaucoma, ps
Aerie Pharmaceuticals — Investor Presentation (August 2019) on 6ix